Pretomanid is indicated for use in a limited and specific population of patients.
- Trade Name: PA-824 (TB Alliance)
- Indications: Part of a combination regimen with bedaquiline and linezolid for the
treatment of adults with pulmonary extensively drug resistant, treatment-intolerant or nonresponsive multidrug-resistant tuberculosis. - Class: Antimycobacterial (including antitubercular)
- Half-life: 17 hours
- FDA Approval Date: 08/14/2019
- Clinically important, potentially hazardous interactions with:
Organic anion transporter-3 substrates, Strong or moderate CYP3A4 inducers - Pregnancy: There are no studies or available data on pretomanid use in pregnant women to inform any drug-associated risks. Breastfeeding is not recommended during treatment with pretomanid or with combination therapies.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 08/21/2025
